. 2016 Feb 16;110(3):163–172. doi: 10.1093/trstmh/trv107

Table 1.

Recent evaluations of short (9 to 12-month) multidrug-resistant TB regimens

Site and date of report	Regimen		No. patients	Time to 95% treatment completion	Treatment success, n (%)		Non-success, n (%)
Site and date of report	Intensive	Continuation	No. patients	Time to 95% treatment completion	Cure	Completed	Failure	Death	Default	Relapse^c
Bangladesh, 2010²⁴	4Km-Cfz-Gh-_-E-Hh-Z-Pto^a	5Gh-E-Z-Cfz	206	365 days	170 (82.5)	11 (5.3)	1 (0.5)	11 (5.3)	12 (5.8)	1 (0.5)
Bangladesh, 2014²⁵	4Km-Cfz-Gh-_-E-Hh-Z-Pto^a	5Gh-E-Z-Cfz	515^b	363 days	418 (81.2)	17 (3.3)	7 (1.4)	29 (5.6)	40 (7.8)	4 (0.8)
Cameroon, 2015²⁶	4Km-Cfz-G-E-H-Z-Pto^a	8G-Cfz-Z-E-Pto	150	409 days	132 (88.0)	2 (1.3)	1 (0.7)	10 (6.7)	5 (3.3)	0

Numbers in front of drug combinations indicate planned months of therapy.

Cfz: clofazimine (50–100 mg); E: ethambutol (800–1200 mg); G: gatifloxacin (400 mg to all patients); Gh: gatifloxacin high dose (400–800 mg); H: isoniazid (300 mg to all patients); Hh: isoniazid high dose (300–600 mg); Km: kanamycin (500–1000 mg); Pto: prothionamide (500–1000 mg); Z: pyrazinamide (800–2000mg). Dose ranges indicate adjustment by weight.

^a Intensive phase therapy extended until sputum smear conversion if not smear negative at 4 months.

^b The second Bangladesh study represents a cumulative total of patients on the ‘Bangladesh’ regimen, so includes longer-term follow-up data on patients from the first study in addition to new data.

^c Completion of 24 month follow-up to detect relapse amongst patients with treatment success was variable between these studies; 54% and 93%, respectively, in the Bangladesh studies and 75% in Cameroon.